Canaccord Adams Maintains a 'Speculative Buy'on AEterna Zentaris (AEZS); Positive FDA Data From Partner Keryx Pharmaceuticals (KERX)
Tweet Send to a Friend
Canaccord Adams maintains a 'Speculative Buy' rating on AEterna Zentaris Inc. (Nasdaq: AEZS), price target $1.65.
Canaccord analyst says, "Partner ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Partner ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
